Search

Senior Finance Associate

PublishedPublished: 6/14/2022

Job Description

About the role:

\n


\n


\n Myt client is looking for a Senior Associate, Finance to own the entire finance function at a fast-growing biotech company digitizing the immune system. You'll report directly to the CEO, taking over from a consulting CFO, and be responsible for everything from closing the books to building production cost models that inform pricing and operational decisions across 30+ clinical trials

\n


\n

.
\n What will you be doin

\n


\n

g?
\n Own monthly close, runway forecasts, and profitability reforecasts — full cutover from the existing consulting

\n

CFOBuild and maintain a production cost model to understand the true cost of serving each drug developer custo

\n

merPrepare board packages, investor updates, and fundraising materi

\n

alsManage accounts payable/receivable and oversee the outsourced bookkeeping firm for accur

\n


\n

acy
\n Take on lateral operations functions as the company scales (supply forecasting, compensation modeling, cap table managem

\n


\n

ent)
\n Key Require

\n


\n

ments
\n Proven ability to build financial models from scratch (operating models, unit economics, margin ana

\n


\n

lysis)
\n Experience managing a month-end close

\n


\n

process
\n Advanced Excel/Google Sheets pro

\n


\n

ficiency
\n Comfortable being hands-on and operating autonomously as the sole fin

\n


\n

ance hire
\n High attention to accuracy — must be detail-oriented with numbers an

\n


\n

d invoices
\n Competi

\n

tive equityOn-site

\n

work policyVisa Sponsors

\n

hip DetailsOpen to visa transfers (e.g. OPT, H1B

\n

transfers)Open to visa sponso

\n


\n

rships (TN)
\n Senior Associ

\n

ate, FinanceFull-t

\n

ime, On-siteSalt Lake City, UT OR S

\n

an Mateo, CA

\n


\n

$80K - $120

\n

K
\n Experience:0 - 5 years of experience in FP&A, investment banking, PE, or con

\n


\n

troller roles
R

\n


\n

esponsilities:
\n Built financial models from scratch (operating models, unit economic

\n


\n

s, forecasting)
\n Managed or supported month- e

\n


\n

nd close process
\n Archetype 1: Investment banking or PE analyst/associate (e.

\n


\n

g. , 1- 3 years)
\n Archetype 2: FP&A or controller at stable company (e. g. , Gilead, Northrop Grumman, Bl

\n


\n

ackrock N

\n

eurotech)
\n EducationNo degree required — skills and output matter mo

\n


\n

re than cre

\n

dentials
\n Hard skillsAdvanced Excel/Google Sheet

\n


\n

s financial modeling
\n Production cost modeli

\n


\n

ng and unit economics
\n AI tool fluency for automa

\n


\n

ting financ

\n

e workflows
\n Soft skillsHands- on executor — willing to do the modeling th

\n


\n

emselves with

\n

out a team
\n MiscellaneousBased in or willing to relocate to Salt Lake City (preferred) or San Mat

\n


\n

eo; on- site 5

\n


\n

days/week
\n About Company:
\n My client is building the Artificial Immunologist. With 500M+ years in the making, the immune system is nature’s original fine-tuned model. We are building a foundational laboratory to digitize this system and reshape multi-billion dollar markets across clinical trials, oncology, autoimmune diagnostics, prenatal medicine, sur

\n


\n

gical recovery, and aging.
\n By capturing high-resolution immune snapshots, we give drug developers and doctors the decisive signal they need to predict whether a $200M+ clinical trial succeeds, whether a therapy will cause irreversible harm, or whether a patient will respond to a crucial drug. Through deep technical breakthroughs, we have cracked the key challenges that have held back immune profiling from achi

\n


\n

eving clinical-grade scale.
\n Today we power 30+ trials for Genentech, Recursion, iOnctura, Obsidian, and many more. Revenue has grown explosively because we solve critical problems that have bedeviled drug developers and doctors for years. Our interdisciplinary team brings together pioneers and experts in immunology, advanced diagno

\n


stics, and machine learning.

Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...